Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Therapy Name||Bortezomib + Dexamethasone + Venetoclax|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Bortezomib||Velcade||Velcade (bortezomib) is a reversible proteasome inhibitor that inhibits survival of malignant cells and regulates bone remodeling (PMID: 26579531). Velcade (bortezomib) is FDA approved for the treatment of mantle cell lymphoma and multiple myeloma (FDA.gov).|
|Venetoclax||Venclexta||ABT-199|RG7601|GDC-0199|ABT119||BCL2 inhibitor 18||Venclexta (venetoclax) is a BH3-mimetic that binds to and inhibits BCL2, resulting in increased tumor cell apoptosis (PMID: 26589495, PMID: 25048785). Venclexta (venetoclax) is FDA approved for use in patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), and in combination with chemotherapy in patients 75 years old or older with newly-diagnosed acute myeloid leukemia (FDA.gov).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||multiple myeloma||not applicable||Bortezomib + Dexamethasone + Venetoclax||Phase III||Actionable||In a Phase III trial (BELLINI), addition of Venclexta (venetoclax) to Velcade (bortezomib) and dexamethasone significantly improved progression-free survival (23.2 vs 11.4 mo, HR=0.60) in patients with relapsed or refractory multiple myeloma, but also increased mortality rate (33%, 64/194 vs 25%, 24/97) and did not improve overall survival (33.5 vs not reached, HR=1.46) (J Clin Oncol 38, no. 15_suppl (May 20, 2020) 8509-8509; NCT02755597).||detail...|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|
|NCT02755597||Phase III||Bortezomib + Dexamethasone Bortezomib + Dexamethasone + Venetoclax||A Study Evaluating Venetoclax (ABT-199) in Multiple Myeloma Subjects Who Are Receiving Bortezomib and Dexamethasone as Standard Therapy||Suspended|
|NCT01794507||Phase I||Bortezomib + Dexamethasone + Venetoclax||A Study Evaluating ABT-199 in Multiple Myeloma Subjects Who Are Receiving Bortezomib and Dexamethasone as Standard Therapy||Completed|